The Alza T IPCS 52, a longer acting progesterone IUD: safety and efficacy compared to the TCu22OC and multiload 250 in two randomized multicentre trials. The World Health Organization's special programme of research, development and research training in human reproduction. Task Force on intrauterine devices for fertility regulation.
The longer-acting progesterone-releasing IUD - the Alza T IPCS 52 - was compared to the TCu22OC and Multiload 250 in two randomized trials in 20 centres in 17 countries. There were 2239, 2292 and 1011 insertions respectively. The copper devices had significantly lower medical removal rates and higher continuation rates. The pregnancy rates for the progesterone releasing device were significantly higher after 390 days of use in the interval insertion study and after 870 days in the post abortion insertion study. The Alza T IPCS 52 device achieved only 2 year efficacy rather than the original objective of 3 years.
D000206:Actuarial Analysis; D000293:Adolescent; D000328:Adult; D000367:Age Factors; D002986:Clinical Trials as Topic; D005260:Female; D006801:Humans; D007433:Intrauterine Device Expulsion; D007436:Intrauterine Devices, Medicated / Q000009:adverse effects; D010298:Parity; D011247:Pregnancy; D011271:Pregnancy, Ectopic / Q000209:etiology; D011374:Progesterone; D011897:Random Allocation; D014595:Uterine Perforation / Q000209:etiology; D014944:World Health Organization
D011374:Progesterone